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Opinion Article 
THE UNBEARABLE LIGHTNESS OF PRESCRIBING GROWTH HORMONE 
Ljiljana Šaranac  
Faculty of Medicine, University of Niš, Niš, Serbia  
Abstract. Short stature is the most visible and prominent physical characteristic and one of the commonest reason for 
referral to pediatric endocrinologist. It is assumed as disabling condition with psychosocial consequences that seeks 
treatment. Behind short stature severe pathology could be hidden, although not necessarily of endocrine origin. Even in the 
new millennium, many diagnostic pitfalls and dilemmas persist in confirmation of growth hormone deficiency (GHD), the 
first indication that fits in endocrine paradigm: to replace the missing hormone. In 1985 FDA approved recombinant human 
GH (hGH) as the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous GH. 
Availability of hGH in unlimited amounts enhanced the number of indications of GH use. Pediatric endocrinologist started 
to promote and to apply use of hGH for height in short, but otherwise healthy children, with hormonal normalcy. 
Reasonable criticism of such praxis arises in the light of recent safety alerts. The unbearable lightness of prescribing growth 
hormone to every apparently or really short child is reaching epidemic progress in Serbia. When authorities in this low 
income country (estimated as developing), approved hGH for use in SGA (small for gestational age) children, use and 
misuse of hGH exploded. Socially acceptable height, the term applied by some endocrinologists actually means that society 
does not accept short people. The pharmaceutical companies go even further offering, besides growth acceleration, better 
and brighter future for potential patients, in whom the self-confidence is measured by centimeters of height. However, 
benefits of such treatment on quality of life were never confirmed. Children with severe growth failure and documented 
GHD should be treated undoubtedly, but use of hGH for height, so called cosmetic endocrinology, needs critical appraisal. 
Children and their parents should be informed about height prediction and long-term consequences. 
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"Even in the most wary mariner may easily 
lose his way as he seeks to steer his bark 
amid the glandular temptations whose siren 
voices have proved the downfall of many 
who have gone before" wrote Boyd in 1943,  
according to Bailey [1] 
Introduction

 
Growth failure due to growth hormone deficiency 
(GHD) is the easiest endocrine disorder to treat and the 
hardest to diagnose [2]. Short stature is the most visible 
and prominent physical characteristic. It is assumed as 
disabling condition with psychosocial consequences that 
seeks treatment. However, benefits of such treatment on 
quality of life were never confirmed. Behind short stat-
ure severe pathology could be hidden, although not nec-
essarily of endocrine origin. Neglecting growth moni-
toring in primary and secondary health care centers re-
sults in delayed diagnosis of severe diseases or plenty of 
inappropriate referrals. A high frequency of diagnostic 
delays is reported for so-called classical target condi-
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tions, such as Turner syndrome, GHD, Crohn’s disease, 
celiac disease and cystic fibrosis. On the other hand, 
inadequate growth monitoring can result in unnecessary 
diagnostic cumbersome investigation [3].  
It was hoped that the discovery by Evans and Long 
in 1921 of a mammalian pituitary gland extract capable 
of producing growth in laboratory animals, would solve 
the problem of short stature in children. However, it was 
not until 1956, when growth hormone from human pi-
tuitary glands was extracted by Raben. In 1957, the ef-
fective treatment was available for the small percentage 
of short children with growth hormone deficiency. GH 
substitution therapy in hypopituitary man, published in 
NEJM by Raben in 1962 was an example of the first 
personalized therapy use [4]. In late 1984, a 20-year-old 
man who was previously treated with cadaveric pitGH 
died from Creutzfeldt-Jakob disease, which led to 
abrupt withdrawal of pitGH in United States. In 1985 
FDA approved recombinant human GH (hGH) as the 
treatment of pediatric patients who have growth failure 
due to inadequate secretion of endogenous GH, and 
shortly after hGH was approved in Europe. Availability 
of hGH in unlimited amounts since 1985, enhanced the 
number of indications of its use (Table 1).  
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Table 1 Approved Indications for hGH use in EU, 
Serbia and USA  
European Union and Serbia United States of America 
 GHD in children and adults  
 Turner Syndrome  
 Small for Gestational Age  
 Prader-Willi Syndrome  
 Chronic Renal Failure 
 GHD* in children and adults 
 Turner Syndrome 
 Small for Gestational Age 
 Prader-Willi Syndrome 
 Chronic Renal Failure 
 Idiopathic Short Stature 
(ISS) 
 SHOX deficiency 
 Noonan Syndrome 
 Short Bowel Syndrome 
 AIDS wasting in Adults 
* GHD  Growth Hormone Deficiency 
For prescribers the availability of abundant amounts of 
recombinant human growth hormone led to introduction of 
hGH for height treatment, and not only for substitution of 
missing hormone or restoring physiological hormonal 
normalcy. The diagnosis of GHD was widen and more 
inclusive by arbitrary raising cutoff diagnostic values in 
provocative testing. The old diagnostic criterion, 
commonly used in the past for GHD in children was peak 
level during stimulation less than 3 ng/mL (very restrictive 
and limited to severe or persistent and true GHD, also 
called „certain" or „definitive GHD"). Paradoxically, as 
GH assays grew more specific, criterion for failing a GH 
stimulation test grew even more generously. Cutoffs rose 
from 3 to 7 ng/mL to the current 10 ng/mL level [5]. MRI 
findings are more cosistent with clinical characteristics of 
GHD and more predictive of response to hGH therapy than 
are peak GH responses in provocative testing. Structural 
abnormalities of the hypothalamic-pituitary region have 
been described on MRI in up to 90% of patients with 
multiple pituitary hormone deficiency (MPHD), suggesting 
that brain MRI may represent the first-line investigation for 
diagnosing GHD, especially in infancy and early childhood 
[5,6]. In 2003, the FDA expanded hGH use to the 
treatment of ISS (Idiopathic short stature), also called non-
GH-deficient short stature, defined by height standard 
deviation score (SDS) <2.25 (<1.2nd percentile). The 
height cutoff of 2.25 SD (1.2nd percentile) corresponds in 
adults to 160 cm for men and 150 cm for women [79]. 
The concept of of ISS is controversial, artificial, arbitary 
and heterogeneous, including normal and patients with 
pathology, but having one thing in common: our ignorance 
to obtain an etiopathogenic diagnosis [5, 8]. 
Short stature is one of the commonest reasons for re-
ferral to most pediatric endocrine clinics. The unbeara-
ble lightness of prescribing growth hormone to every 
apparently or really short child is reaching epidemic 
progress in Serbia. When authorities in this low income 
country (estimated as developing), approved hGH for 
use in SGA (small for gestational age) children, use and 
misuse of GH exploded. Without any serious estimation 
of pro and contra reasons, many times under pressure of 
parents, children get GH. Even children with failure to 
thrive because of gluten intolerance or caloric restriction 
due to poverty, get hGH therapy, as result of superficial 
investigation or misdiagnosis. Medical doctors without 
any international reference travel across the planet 
sponsored by pharmaceutical industry, get a big hono-
raria promoting that bigger is better and even healthier. 
But, children are not so happy with their daily injec-
tions. The height gain is variable as myriad of reasons 
influencing growth are in game. The average increase in 
adult height after multiple years of treatment ranged 
from 3.56 to 7.56 cm. The question arises whether an 
average height gain of 5cm should be considered as 
satisfactory taking into account the cost of 70 000 $ for 
such gain (or 10,000$-60,000$ per patient year), besides 
pain of daily injections and discomfort of frequent peri-
odic clinical investigations [911]. 
Thus the arrival of recombinant hGH shifted basic 
endocrine paradigm in endocrinology: to substitute defi-
cient hormone and to suppress hyperfunction or; physi-
ological hGH replacement to pharmacological hGH 
therapy for height enhancement [9]. This new statement 
is not free of potential severe consequences. As key 
opinion leader, Allen DB emphasized that there is in-
creasing uncertainty about the real benefits and potential 
risks of hGH therapy for many thousands of short, but 
otherwise healthy children [9,10]. Applying hGH in 
children with hormonal normalcy as in ISS is common 
decision of parents and doctors. Laventhal et al. [11] 
describe this complex relationship as a tango for three 
(patients and their parents, doctors willing to prescribe 
and regulators ready to approve and to pay for its use). 
As De Vries noticed [12] they do not mention a fourth 
dancer: the pharmaceutical companies. Marketing strat-
egies of these companies result in intense and close 
doctor-industry relationships and could influence doc-
tors’ prescribing practices [1315]. Prescribers of hGH 
became "investigators" whose institution or even they 
personally, received per-patient compensation for de-
tection, treatment and follow-up and reporting hGH-
treated patients [10, 15]. Recent articles published in 
Hormone Research in Pediatrics and in The New Eng-
land Journal of Medicine summarize all important is-
sues in this area. They attracted my attention by reason-
able criticism of cosmetic endocrinology and also re-
vealed new, brilliant explanation of such phenomenon, 
lurking behind the scene [9, 10,15]. 
GH Effects beyond Height 
Many teenagers with GHD have poor bone strength, 
fatigue and lack of stamina, as well as depression, lack 
of concentration, poor memory and anxiety problems. 
As a mother of one GH deficient child said: "GHD isn’t 
just about growth, as lack of growth hormone impacts 
the child in many ways, such as lack of strength and 
they can find it difficult to keep up physically with their 
peers. It impacts the child self-esteem as they are often 
treated as being much younger, because of their size" 
[16]. GH treatment allows the child to growth to their 
genetic potential. Majority of short people have life-
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long problem in finding appropriate clothes and shoes, 
or purchase in children’s stores, because shops do not 
carry their size [17]. Severe short stature is no doubt, 
physically debilitating requiring special accommoda-
tions for reaching shelves or driving [15]. 
Components of GH-IGF-1 axis make an important 
contribution to the development, function, regeneration 
and neuroprotection of the CNS. GH plays well estab-
lished roles in neurogenesis, axonal elongation and for-
mation of oligodendrocytes, astrocytes and glial cells, as 
well as in angiogenesis, synaptogenesis, and synaptic 
transmission and prevention of neuronal apoptosis 
[18,19]. Indeed in patients with congenital classic triade 
syndrome, we were informed by parents about im-
provement in maturity and positive behavioral changes. 
Namely, true GHD shows not only impairment in psy-
chological well-being but also defects in attention, 
memory and executive function, with evidence of im-
provement in cognitive function after GH replacement 
[1820]. This effect is more evident in "definite GHD" 
and it is obtained at least partly by stimulating T4 to T3 
conversion with great impact on neurodevelopment. 
The discontinuation of treatment in adolescents with 
GHD after completion of linear growth may be associ-
ated with adverse effects on body composition, lipid 
profile, and cardiac morphology [18]. 
While people tend to attribute significantly less 
favorable characteristic to short persons, research 
repeatedly in majority of studies fails to detect an excess 
of psychosocial adaptation problems among short-
statured youths [15]. Socially acceptable height, the term 
used by some endocrinologists actually means that 
society does not accept short people. The pharmaceutical 
companies go even further and offer, not only growth 
acceleration and improvement of final height as result of 
GH therapy, but also better and brighter future for 
potential recipients in whom the self-confidence is 
measured by centimeters of height. As Allen DB noticed: 
„It is too good to be all good" [15]. Is hGH „panacea or 
Pandora's box?" he asked [21]. A trend of exaggeration of 
hGH use for height, „heightism" [21,22] remainds me of 
sociopathic virus of fear of aging („ageism"), also 
imported in Europe from USA. Justification of hGH use 
for height needs confirmation that this treatment is safe 
and free of serious short term and long term adverse 
events. These phantastic references also led me to 
publications of Samaras concerning of logevity regarding 
height. Within generally healthy conditions short people 
live longer. Most centenarians tend to be short or small. It 
is best to be short and lean and to restrict protein intake. 
One mechanism supporting the "shorter and smaller is 
better" thesis is somatic cell duplication potential. Bigger 
bodies use up more cell replications during their 
maturation, because they contain more cells. It takes 
more cells to build and maintain a bigger body, and more 
cells increase the risk in cancer in taller people. Big 
people cost more [2325]. Disruption of the GH-IGF-1 
axis may result in increased longevity [26].  
Safety Issues 
Occurrence of adverse events during hGH treatment as 
intracranial hypertension, glucose intolerance, a slipped 
capital femoral epiphysis is well known and its 
incidence is low [27]. Physician’s discussions with 
families must involve honest and realistic appraisal of 
treatment expectations for height gain [11]. It is worri-
some that serious adverse events usually are not dis-
cussed. Post marketing studies sponsored by pharma-
ceutical companies, manufacturers of hGH so far re-
ported only short term adverse events. Short term ef-
fects are not long term effects, more precisely; long 
term effects are still unknown. This statement does not 
refer to GH deficient subjects on hGH substitution ther-
apy, but to hGH applied for height in healthy children. 
When the announcement on increased mortality in 
GH treated individuals reached the headlines a lot of 
anxiety was produced in professional and scientific 
community as well as in GH recipients and their fami-
lies [28]. The study on the Safety and Appropriateness 
of GH treatments in Europe (SAGhE study) announced 
that that the observation of long-term outcomes of chil-
dren treated with hGH between 1985 and 1996, revealed 
a significant excess mortality (93 deaths vs. 70 expected 
from an age-matched population in France) [29]. Addi-
tionally a follow-up of 30 000 low-risk children treated 
with hGH between 1980 and 1990 in 8 European coun-
tries, who had reached 18 years of age between 2009-
2010 was performed. Patients were classified as low 
mortality risk if they were diagnosed as idiopathic 
GHD, SGA, or ISS without genetic syndrome or de-
fects. Patients with renal failure, short stature syndrome, 
like Turner syndrome, and tumor survivors were ex-
cluded. A preliminary report from France on 6928 low-
risk children with mean follow-up of 17.34.1 years 
from the start of therapy showed an increase in the 
overall standardized mortality ratio. The increase in all-
cause mortality was associated with a higher hGH dose 
of >50 µg/kg/day, but not with the severity of GHD or 
the duration of total GH exposure. Increased mortality 
rate was due to bone tumors, cardiovascular events and 
cerebrovascular hemorrhage [2830]. Results have not 
been reproduced by reports from other countries partici-
pating in the study. Among 21 deaths identified, 12 
were due to accidents, four were suicides, and one pa-
tient each died from pneumonia, endocrine dysfunction, 
primary cardiomyopathy, deficiency of humoral im-
munity, and coagulation defect [31]. The question of 
whether GHD per se is associated with an increased 
mortality, taking into account that pituitary produces 
LIF (Leukemia Inhibiting Factor) is for debate. It is 
strongly recommended by health authorities that hGH 
should be given to those who need it and the dose 
should be kept in the range given in the clinical trials 
that led to the registration of the medication [7,10,28]. 
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The Situation in Serbia 
Pediatric endocrinologists and pediatricians in Serbia 
embraced hGH use ever since its approval. We have 
published in 2004, Guidelines for early detection and 
treatment of children with congenital and acquired 
GHD, Turner syndrome and SGA. The publication in 
Serbian is result of team work, in accordance with 
Growth Hormone Research Society Consensus Guide-
lines for the treatment of GHD. Although not free of 
imperfections and confounders this recommendations 
contributed a lot in clarifying this complex area [32,33]. 
A plenty of periodical lectures are given, targeting pedi-
atricians in Primary Health Care as a first line doctors, 
supposed to recognize and to refer short stature patients 
to Pediatric clinics with certified pediatric- endocrinolo-
gists. And this strategy works with regard to number of 
GHD children on hGH therapy in Serbia. However, the 
diagnosis of GHD is still made too late; in prepubertal 
or pubertal age. Unfortunately some short patients are 
referred after achievement of final heght. Data from the 
International Outcome Study (IOS) confirmed late 
referral of Serbian GHD children. The mean age at 
treatment start in Serbia is 11.23.5 years in comparison 
to 8.24.1 years in Czech Republic [34]. And vice versa 
non GHD children are often diagnosed as deficient due 
to reliance on GH provocative tests as the main 
diagnostic criterion of GHD [5,7]. The auxology is used 
as tool for detecting candidates for hGH treatment and 
not to establish accurate and exact diagnosis. Many 
clinical doctors are crossed planet due to medical 
tourism sponsored by hGH manufacturers; namely it is 
hardly to find any point, where some prescribers of hGH 
have never been. It is worthy to say that some of us are 
active in presenting Serbian results in the field all over 
the world and that it would be impossible without 
sponsorship [3545]. What should be Serbian pediatric 
endocrinologist devoted to, in the light of new safety alerts. 
We must take seriously recent warnings and be engaged in 
raising awareness about potential short term and long term 
harmful effects of hGH, with the same effort used in 
promotion of hGH use. At least we must inform our 
patients about new discoveries and to practice not only 
parent's informed consent, but also children's assent, as 
experts from Unated states and Europe suggest. Finally as 
mentioned above to avoid cosmetic endocrinology and to 
be cost-conscious of such treatment in all aspects [15,22]. 
We must resist to siren voices and unbearable lighteness of 
prescribing growth hormone. Diagnosis of short stature and 
its treatment is not for the amateurs. Serious life-
threatening diseases could be part of pituitary dysfunction 
and investigation of adrenal and thyroid axes should be the 
first diagnostic step. Pituitary disorders that need urgent, 
life-saving diagnosis are, present even at birth [46]. 
Cosmetic endocrinologists, obsessed with „heightism" are 
not involved in this process. Some of them are 
unfortunately only „growth- hormonologists". 
Even in this genocentric millennium nothing could 
replace simple and accurate height and weight meas-
urements, staying in touch with phenotypes, clinical 
curiosity and honesty. Nothing compares to satisfaction 
get by normalization of child’s growth. Growth moni-
toring of apparently healthy children aims at early de-
tection of serious underlying disorders. 
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